SG10201900504XA - Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases - Google Patents

Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases

Info

Publication number
SG10201900504XA
SG10201900504XA SG10201900504XA SG10201900504XA SG10201900504XA SG 10201900504X A SG10201900504X A SG 10201900504XA SG 10201900504X A SG10201900504X A SG 10201900504XA SG 10201900504X A SG10201900504X A SG 10201900504XA SG 10201900504X A SG10201900504X A SG 10201900504XA
Authority
SG
Singapore
Prior art keywords
eosinophilic
treatment
glutarimide derivatives
pharmaceutical composition
diseases
Prior art date
Application number
SG10201900504XA
Other languages
English (en)
Inventor
Vladimir Evgenievich Nebolsin
Tatyana Alexandrovna Kromova
Anastasia Vladimirovna Rydlovskaya
Alexander Grigorievich Chuchalin
Original Assignee
Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises filed Critical Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises
Publication of SG10201900504XA publication Critical patent/SG10201900504XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • C07D211/88Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201900504XA 2013-11-14 2014-11-12 Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases SG10201900504XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Publications (1)

Publication Number Publication Date
SG10201900504XA true SG10201900504XA (en) 2019-02-27

Family

ID=53057723

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201900504XA SG10201900504XA (en) 2013-11-14 2014-11-12 Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases

Country Status (23)

Country Link
US (2) US9949962B2 (sr)
EP (2) EP3069720B1 (sr)
JP (4) JP2016540749A (sr)
KR (2) KR102312013B1 (sr)
CN (2) CN105722511B (sr)
AU (2) AU2014349246C1 (sr)
BR (1) BR112016010515B1 (sr)
CA (1) CA2930231C (sr)
CY (1) CY1122500T1 (sr)
DK (1) DK3069720T3 (sr)
EA (4) EA032940B1 (sr)
ES (2) ES2836887T3 (sr)
HU (1) HUE046671T2 (sr)
IL (2) IL245429B (sr)
LT (1) LT3069720T (sr)
MX (2) MX365781B (sr)
PL (2) PL3069720T3 (sr)
PT (1) PT3069720T (sr)
RU (1) RU2552929C1 (sr)
SG (1) SG10201900504XA (sr)
SI (1) SI3069720T1 (sr)
UA (1) UA118687C2 (sr)
WO (1) WO2015072893A1 (sr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110128406B (zh) * 2013-04-12 2021-08-27 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
KR20240128110A (ko) 2014-02-28 2024-08-23 리제너론 파아마슈티컬스, 인크. Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법
MA46098A (fr) 2016-09-01 2019-07-10 Regeneron Pharma Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
EA039391B1 (ru) * 2017-09-07 2022-01-21 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
WO2020191346A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
SG11202113312VA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
CA3147113A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN115803026A (zh) * 2020-06-26 2023-03-14 瓦伦塔有限责任公司 戊二酰亚胺衍生物用于治疗与异常白介素-6活性相关的疾病的用途
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196767A (ja) * 1988-10-11 1990-08-03 Kyowa Hakko Kogyo Co Ltd ヒドロキサム酸誘導体
CA2097607A1 (en) 1990-12-24 1992-06-24 Marcel Hibert Use of certain glutarimide derivatives in the treatment of depression and mania
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
PL369863A1 (en) 2001-11-07 2005-05-02 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
ES2558689T3 (es) 2007-05-14 2016-02-08 Medimmune, Llc Métodos para reducir los niveles de eosinófilos
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств
CN110128406B (zh) 2013-04-12 2021-08-27 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法

Also Published As

Publication number Publication date
IL271352B (en) 2021-04-29
ES2759530T3 (es) 2020-05-11
CN105722511A (zh) 2016-06-29
AU2014349246C1 (en) 2019-02-21
EA037447B1 (ru) 2021-03-30
KR20200053639A (ko) 2020-05-18
CN105722511B (zh) 2019-09-17
IL245429B (en) 2020-02-27
JP6589251B2 (ja) 2019-10-16
SI3069720T1 (sl) 2020-02-28
EA032955B1 (ru) 2019-08-30
CA2930231C (en) 2022-06-14
CA2930231A1 (en) 2015-05-21
EA201990529A1 (ru) 2019-07-31
MX2019006881A (es) 2019-08-01
AU2018264084A1 (en) 2018-12-06
US20160279114A1 (en) 2016-09-29
EA201891262A1 (ru) 2018-10-31
EP3466425A1 (en) 2019-04-10
JP2019214606A (ja) 2019-12-19
CN110200968A (zh) 2019-09-06
AU2014349246A1 (en) 2016-05-19
RU2552929C1 (ru) 2015-06-10
JP6758677B2 (ja) 2020-09-23
KR102312013B1 (ko) 2021-10-15
PL3069720T3 (pl) 2020-05-18
ES2836887T3 (es) 2021-06-28
UA118687C2 (uk) 2019-02-25
MX2016006330A (es) 2016-09-06
AU2014349246B2 (en) 2018-10-18
JP2016540749A (ja) 2016-12-28
BR112016010515B1 (pt) 2022-09-27
EA032940B1 (ru) 2019-08-30
US9949962B2 (en) 2018-04-24
JP2019055953A (ja) 2019-04-11
EP3069720A8 (en) 2017-10-04
KR102312294B1 (ko) 2021-10-15
US20180104230A1 (en) 2018-04-19
AU2018264084B2 (en) 2020-05-14
LT3069720T (lt) 2020-01-10
PL3466425T3 (pl) 2021-04-06
RU2013150861A (ru) 2015-05-20
AU2014349246A9 (en) 2018-09-20
AU2018264084C1 (en) 2020-08-27
JP2020002152A (ja) 2020-01-09
EA201690798A1 (ru) 2016-08-31
DK3069720T3 (da) 2019-11-25
KR20160078400A (ko) 2016-07-04
EP3069720A4 (en) 2017-06-21
EP3069720B1 (en) 2019-10-30
WO2015072893A1 (ru) 2015-05-21
EP3466425B1 (en) 2020-10-07
PT3069720T (pt) 2019-12-02
EP3069720A1 (en) 2016-09-21
IL245429A0 (en) 2016-06-30
BR112016010515A2 (sr) 2017-08-08
IL271352A (en) 2020-01-30
US10220029B2 (en) 2019-03-05
EA032955B3 (ru) 2020-02-27
HUE046671T2 (hu) 2020-03-30
MX365781B (es) 2019-06-13
CY1122500T1 (el) 2021-01-27
EA201891261A1 (ru) 2018-10-31
EA030961B1 (ru) 2018-10-31

Similar Documents

Publication Publication Date Title
SG10201900504XA (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
IN2014DN09352A (sr)
IN2014DN09348A (sr)
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
WO2011051490A3 (en) Heterocyclic derivatives
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
IN2014DN09347A (sr)
BR112014004447A2 (pt) bifenilcarboxamidas como inibidores de quinase rock
IN2012DN00239A (sr)
IN2012DN00763A (sr)
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2015007488A (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib.
WO2014106826A3 (en) Anthracycline analogue and uses thereof
MX2014002141A (es) Carboxamidas de n-(5-cicloalquil - o 5-heterociclil-)-piridin-3-il o.
MX2014001862A (es) 5-cicloalquil-o 5-heterociclil-nicotinamidas.